ArticleIntensive care medicine experimental2026
Development and evaluation of machine learning-based prediction-modelling for initial vancomycin serum concentrations in septic ICU patients using clinical health record data.
Article in Intensive care medicine experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis remains a life-threatening condition with highly heterogeneous and dynamic pathophysiology, limiting the effectiveness of uniform therapeutic strategies. Beyond timely source control, antimicrobial therapy represents the only causal treatment option. Vancomycin is widely used for treatment of Gram-positive infections; however, optimal dosing in septic patients is challenging due to pronounced pharmacokinetic variability and substantial interindividual heterogeneity. Underdosing may promote antimicrobial resistance, whereas overdosing increases the risk of toxicity. This study aimed to develop and validate a machine learning-based prediction model to support individualized vancomycin dosing using routinely available clinical data.
methodsThis single-center retrospective study included adult sepsis patients admitted to the intensive care unit, using routinely collected data from the hospital's electronic medical records. Patients were eligible if they received a vancomycin loading dose followed by continuous infusion and had at least one measured serum concentration. Three machine learning models-elastic net regression, random forest, and XGBoost-were developed to predict the initial vancomycin serum concentration. To minimize bias and enhance generalizability, model training, hyperparameter tuning, and performance evaluation were conducted using a stratified nested cross-validation approach. Model performance was compared with seven commonly used population pharmacokinetic models.
resultsThe developed best performing elastic net model achieved a notable improvement with an average RMSE of 6.19, compared to 7.83 for the best pharmacokinetic model highlighting the potential of early and individualized dosing supported by a machine learning model. Final model analysis revealed that noradrenaline administration, together with classical pharmacokinetic parameters including body weight, serum creatinine, and the presence of chronic kidney disease, significantly influenced predictive performance.
conclusionsThis machine learning-based approach for predicting initial vancomycin serum concentrations outperforms conventional PK models and enables more precise, individualized dosing prior to the availability of therapeutic drug monitoring results. By integrating key clinical variables, the model facilitates data-driven decision-making in sepsis care and underscores the potential of machine learning to advance personalized antimicrobial therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.